DNM1 and hepatocellular carcinoma: As a proof-of-concept pharmacological inhibition of the fatty acid transport protein 2 (FATP2) by CB16.2 and of dynamin, which functions as a large GTPase in vesicle transport and the regulation of endocytosis, was investigated in human hepatoma cell cultures.